Abstract:Introduction: During HIV infection the severe depletion of intestinal CD4 T-cells is associated with microbial translocation, systemic immune activation, and disease progression. This study examined intestinal and peripheral CD4 T-cell subsets reconstitution under combined antiretroviral therapy (cART), and systemic immune activation markers. Methods: This longitudinal single-arm pilot study evaluates CD4 T cells, including Th1 and Th17, in gut and blood and soluble markers for inflammation in HIV-infected individuals before (M0) and after eight (M8) months of cART. From January 2010 to December 2011, 10 HIV-1 naı̈ve patients were screened and 9 enrolled. Blood and gut CD4 T-cells subsets and cellular immune activation were determined by flow-cytometry and plasma soluble CD14 by ELISA. CD4 Th17 cells were detected in gut biopsies by immunohistochemistry. Microbial translocation was measured by limulus-amebocyte-lysate assay to detect bacterial lipopolysaccharide (LPS) and PCR Real Time to detect plasma bacterial 16S rDNA. Results: Eight months of cART increased intestinal CD4 and Th17 cells and reduced levels of T-cell activation and proliferation. The magnitude of intestinal CD4 T-cell reconstitution correlated with the reduction of plasma LPS. Importantly, the magnitude of Th17 cells reconstitution correlated directly with blood CD4 T-cell recovery. Conclusion: Short-term antiretroviral therapy resulted in a significant increase in the levels of total and Th17 CD4 T-cells in the gut mucosa and in decline of T-cell activation. The observation that pre-treatment levels of CD4 and of CD8 T-cell activation are predictors of the magnitude of Th17 cell reconstitution following cART provides further rationale for an early initiation of cART in HIV-infected individuals. Trial Registration: ClinicalTrials.gov NCT02097381 Citation: d’Ettorre G, Baroncelli S, Micci L, Ceccarelli G, Andreotti M, et al. (2014) Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE 9(10): e109791. doi:10.1371/journal. pone.0109791 Editor: Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Italy Received April 13, 2014; Accepted September 4, 2014; Published October 23, 2014 Copyright: 2014 d’Ettorre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper, anyway the complete database is freely available from the archive of Department of Public Health and Infectious Diseases of University of Rome ‘‘Sapienza’’ (Italy). This is because the Italian law on privacy does not allow the online publication of complete databases with sensitive data. All data are available upon request contacting Dr. Gabriella d’Ettorre MD PhD. Department of Public Health and Infectious Diseases. Viale del Policlinico 155 (00161) Rome (Italy). Tel 0039-06-49970313, fax 0039-06-49972625, email gabriella.dettorre@uniroma1.it. Funding: This work was supported by ISS ‘‘Programma Italia Usa’’ (to AM) and by National Institutes of Health grant R01-AI-084836 (to MP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * Email: gabriella.dettorre@uniroma1.it PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109791

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

Oral Microbiota is Associated with Immune Recovery in Human Immunodeficiency Virus-Infected Individuals

Increased Microbial Translocation is a Prognostic Biomarker of Different Immune Responses to ART in People Living with HIV

Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients

Viral and Immune Risk Factors of HIV Rebound after Interruption of Antiretroviral Therapy

Correlation of Oral Microbiota with Different Immune Responses to Antiretroviral Therapy in People Living with HIV

Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy

Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: an Observational Study in A Chinese Population

Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals

Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption

Major depletion of insulin sensitivity-associated taxa in the gut microbiome of persons living with HIV controlled by antiretroviral drugs

Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV

Inflammatory Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia

Reconstitution of Intestinal CD 4 and Th 17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects : Implication for Residual Immune Activation from the Results of a Clinical Trial

Genetic Characterization Of Rebounding Hiv-1 After Cessation Of Highly Active Antiretroviral Therapy

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound

Alterations of the gut microbiome in HIV infection highlight human anelloviruses as potential predictors of immune recovery

The Imbalance Between Intestinal Th17 and Treg Cells Is Associated with an Incomplete Immune Reconstitution During Long-Term Antiretroviral Therapy in Patients with HIV.

Soluble markers of viral rebound and post-treatment HIV control

Abnormal blood microbiota profiles are associated with inflammation and immune restoration in HIV/AIDS individuals

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men